Lifting Weights Three Times a Week Cut Muscle Loss on Tirzepatide by a Quarter and Raised Strength 10%, a 120-Person Trial Finds, as a 2,000-Person Study Ties Coached Lifestyle Change to Sharper Aging Brains and Hone Health Raises $228 Million

The fastest-growing drugs in medicine melt away fat, but they also take some muscle with it, and for anyone in their fifties or sixties that trade-off matters for how well they age. A randomized trial from Australia now puts hard numbers on a simple fix: three weight-training sessions a week let people on tirzepatide keep more of their lean tissue and actually get stronger, while those who skipped the gym got weaker. Nature spotlighted the result on November 20, the same week a separate two-year U.S. study tied better heart-health numbers to sharper thinking in older adults, and longevity clinic Hone Health raised $228 million to sell data-driven healthspan care.

What the T-REx trial found

The Tirzepatide and Resistance Exercise (T-REx) study, led by Winthrop Professor Danny Green of the University of Western Australia’s HealthSpan Institute and published in Nature Medicine, followed 120 men and post-menopausal women aged 50 to 70. All had obesity, or were overweight with a weight-related health problem, and none had type 2 diabetes. Every participant took weekly tirzepatide, the drug sold as Mounjaro, for 40 weeks, with most tolerating the full 15 mg dose. Half were also assigned to supervised resistance training three times a week, and they showed up for 91% of sessions.

Both groups lost roughly the same amount of weight, about 22.6 kg without training and 22.3 kg with it, and both shed more than 17 kg of fat. The difference showed up in what was left behind:

  • Lean tissue: the drug-only group lost 4.67 kg of lean soft tissue, versus 3.57 kg for the lifters, a gap of about 1.1 kg. The university’s announcement describes that as 25% less lean-tissue loss.
  • Arms and legs: loss of limb lean mass, the part most closely linked to mobility, was also smaller (3.55 kg versus 2.92 kg).
  • Strength: people on tirzepatide alone lost about 4 kg on the bench press, lat pulldown and knee extension. The training group gained 4.7 kg, 8.6 kg and 5.9 kg on the same lifts. By UWA’s estimate, strength rose about 10% with training and fell about 10% without it.

Green’s argument is that the goal of these drugs should be better health and function, not just a lower number on the scale. In his view, pairing them with weight training should in theory mean more healthy, independent years of life. The trial was investigator-initiated. Tirzepatide’s manufacturer supplied the drug free of charge but, according to UWA, played no part in designing or evaluating the study.

Why muscle is a longevity issue, not a vanity metric

Muscle and strength in later life go hand in hand with balance, independence and recovery from illness, which is why the age band in this trial matters. Some losing of lean mass happens with any kind of weight loss, as Green points out, but GLP-1-class drugs now routinely take off 20% to 25% of body weight, so the scale of the change is new. Nature‘s research highlight summed the finding up as weightlifting partly preventing the muscle loss caused by some obesity drugs.

Not every expert sees the lean-mass number as the main point. A Washington Post report this week stressed strength relative to body weight, which can improve as weight drops even when some muscle goes. Either way the advice is the same: people on these drugs should be lifting.

A second signal: structured programs beat going it alone

The muscle finding fits a broader pattern in this week’s healthy-aging research: supervision and structure produce measurably better results. New results from the Alzheimer’s Association’s U.S. POINTER trial, reported by Medical News Today on November 20 with primary results in JAMA, followed more than 2,000 sedentary, at-risk adults averaging about 68 years old. They were randomly assigned to a structured or a self-guided program built on exercise, the MIND diet, social and mental engagement, and health monitoring.

After 24 months, the structured group showed significantly larger improvements in BMI, diastolic blood pressure, HbA1c, LDL cholesterol, triglycerides, total cholesterol, resting heart rate and waist size. In both groups, bigger gains in those heart-and-metabolism measures went along with better overall cognition. UC Davis epidemiologist Rachel Whitmer, a principal investigator, called it gold-standard evidence that cardiovascular risk can be lowered quickly in a high-risk group. An alumni extension will follow participants for four more years to see whether the brain benefits last.

The business angle: healthspan is becoming a service industry

Investors are betting on exactly this kind of guided care. On November 18, New York-based Hone Health announced $228 million in financing: $28 million of Series A equity led by MarcyPen Capital Partners, plus $200 million in growth financing from General Catalyst’s Customer Value Fund. The company says it has treated more than 200,000 patients and run 750,000 tests. It already offers weight management and DEXA body-composition scans (the same type of scan T-REx used to measure lean mass), and it plans to add programs in metabolic health and inflammation, more diagnostics and a high-end concierge tier that tracks more than 1,600 markers.

For business readers, a few takeaways stand out:

  • Bundling is the opportunity. Telehealth weight-loss providers, gyms, physical therapists and employer wellness programs that pair a prescription with coached strength training now have randomized evidence to point to.
  • Structure is the product. In both T-REx and POINTER, supervision and accountability made the difference. Coaching, check-ins and follow-up drive the results, and they are also where the recurring revenue comes from.
  • Outcomes are shifting from pounds to function. Clinics and insurers that measure strength and body composition, not just weight, will be better placed as payers ask what they are getting for costly GLP-1 coverage.

The bottom line

Weight-loss drugs are turning into a mass-market healthy-aging tool, and this week’s research shows that the drug alone is only part of the answer. Three sessions of weight training a week cut lean-tissue loss by about a quarter and turned a strength decline into a gain. A coached lifestyle program also beat a do-it-yourself plan on heart and metabolic risk. The companies that provide that structure at scale stand to gain.

Sources: Nature Medicine (T-REx trial); University of Western Australia; Nature research highlight; Medical News Today (U.S. POINTER); The Washington Post; Hone Health via PR Newswire.

Running a clinic, gym or wellness practice? When a health trend takes off, new patients call at all hours. MAJ.COM Voice AI gives you 24/7 AI voice agents that answer every inbound call, book consultations and handle outbound follow-ups and customer support, so you never miss a lead.

Edited by Coron @QUE.COM
Website: https://QUE.COM Intelligence
Sponsored by: https://MAJ.COM AI Autonomous


Discover more from QUE.com

Subscribe to get the latest posts sent to your email.

Coron @QUE.COM

Editor at QUE.com Intelligence.

coronquecom has 219 posts and counting.See all posts by coronquecom

Leave a Reply

Connect with

Discover more from QUE.com

Subscribe now to keep reading and get access to the full archive.

Continue reading